Satellos submits IND to FDA for Phase 2 SAT-3247 Clinical Trial in Duchenne Muscular Dystrophy
Satellos Bioscience announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), along with parallel regulatory...
FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy
Nippon Shinyaku announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NS-051/NCNP-04 which is being developed for the...
Italfarmaco and Multicare Pharma Sign Exclusive Distribution Deal for Givinostat (Duvyzat), a DMD Treatment in Brazil
Italfarmaco announced an exclusive agreement with Multicare Pharma, a prominent pharmaceutical company in Latin America. Multicare Pharma will support the regulatory approval in Brazil...
Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial
Avidity Biosciences announced positive new data from participants treated continuously with del-zota for one year in the EXPLORE44 and EXPLORE44-OLE trials. These data demonstrated...
Belief BioMed Announced Successful Completion of First Dose of BBM-D101 Gene Therapy
Belief BioMed, an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that the registration clinical trial (CTR20252461) of its independently developed...